Standard BioTools completed the merger with SomaLogic in a $1bn deal.

Standard BioTools, an analytical laboratory instrument manufacturing company, completed the merger with SomaLogic, a protein biomarker discovery and clinical diagnostics company, in a $1bn deal. “This is an exciting day as we officially bring together the innovative multi-omic technologies and incredible talent of Standard BioTools and SomaLogic to create one company that is a diversified leader in life sciences tools. We are moving forward with a significantly expanded and diversified platform, greater financial flexibility and an accelerated path to profitability. As a larger well-capitalized company, we have greater capacity to self-fund future growth initiatives and accelerate research insights across the industry, better serving our customers and delivering sustainable long-term growth for our shareholders. We are focused on ensuring a smooth transition and achieving our stated commitments,” Michael Egholm, Standard BioTools President and CEO. On December 29, 2023, independent proxy advisory firm Glass Lewis recommended all Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic.